Navigation Links
Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang
Date:4/23/2010

MORRISVILLE, N.C., April 23 /PRNewswire/ -- Asymchem Laboratories is proud to announce and welcome Dr. Guojie (George) Xu as Director of Formulation Development, Dr. Pingzhong Huang as Director of Chemical Development, and Dr. Xiaojun Huang as Senior Director of Chemical Development.

Dr. Guojie (George) Xu joined Asymchem on February 1, 2010.  He brings extensive scientific and managerial experience in pharmaceutical formulations to Asymchem.    Dr. Xu was most recently Product Development Manager at Sandoz, where he held roles of increasing responsibility over 10 year.  Educated in China, he went on to earn a Ph.D. in Pharmaceutics from Meijo University in Japan and held appointments at Shenyang Pharmaceutical University, Beijing Institute for Pharmacology & Toxicology, and the University of Chicago.  Dr. Xu splits his time between Asymchem's Morrisville, NC headquarters and Life Science Center in Tianjin, China.

Dr. Pingzhong Huang joined Asymchem on March 15, 2010.  He brings 15 years of experience in contract synthesis and pharmaceutical process chemistry to the job, most recently at Wyeth in Pearl River, New York where he was a Senior Research Scientist in the Chemical Sciences group.  Dr. Huang graduated from Peking University and earned a Ph.D. in synthetic organic chemistry at the University of Geneva.  Dr. Huang splits his time between Asymchem's Morrisville, NC headqu
'/>"/>

SOURCE Asymchem Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Three Steps to Boost Asymchems Investment in China
2. Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem
3. Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development
4. Codexis Appoints Singapore Laboratories Managing Director
5. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
6. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
7. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
8. Stiefel Laboratories Appoints Two New Members to Board of Directors
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
10. ARUP Laboratories Releases ARUP Consult(R) 2.0
11. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... Md. , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Zola P. Horovitz , Ph.D., from its board of directors ... board in August 2003, and served as its chairman from ... served on the Nominating and Corporate Governance and Audit Committees ... for more than a decade of dedicated service to GenVec, ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... HEIDELBERG, Germany, September 16 , ... Approach Identifies new,Potential Drug Targets in Wnt Pathway , ... inhibition,stabilizes axin and antagonizes Wnt signalling"** is now available online ... Cellzome,s quantitative chemical proteomics,platform was used to identify a small ...
... , , SAN ... College), a private medical school with more than 1,100 physicians, in ... solution to track, manage and report adverse and near-miss events, as ... Manager (EM) and Claims Manager (CM) modules, part of the SRM ...
... , SAN DIEGO, Sept. 16 Hollis-Eden Pharmaceuticals, ... of a new class of small molecule compounds based on endogenous ... The NASDAQ Stock Market on September 15, 2009. , , ... with Nasdaq Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because ...
Cached Biology Technology:Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway 2The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 3
(Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... Accurate knowledge regarding Ebola is critical and pertinent for ... hazardous global outbreak and epidemic. The Journal, Disaster ... special issue, Ebola Virus and Public Health, to surround ... in this critical societal moment. , On October ... for Clinicians . The primer was prepared by Dr. ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... in Uganda who self-paid for their antiretroviral medications experienced ... or supply logistical disruptions. These treatment interruptions led ... patients. , These findings by a team led by ... Kampala, and UCSF are reported in the April 22, ...
... pediatric specialists at Baylor College of Medicine have discovered a ... that allows drugs to enter cancer cells. , The research ... and Biomolecular Chemistry. , All living cells defend themselves ... form a protective cocoon around the cell's inner machinery and ...
... cells to turnover their contents, something that they do ... and radiation, but it is not known if this ... survive the anti-cancer therapy. However, in a study using ... the University of Pennsylvania have now shown that autophagy ...
Cached Biology News:Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2Buckyballs used as 'passkey' into cancer cells 2
Request Info...
... is a new product number, created ... If showing no availability yet, please ... (Z71,405-4) or contact customer service for ... volume diam. 3 mL ...
Contact us for more information...
... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... can be used for gap filling, localized ...
Biology Products: